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Strong Binding of Platelet Integrin 
αIIbβ3 to Fibrin Clots: Potential 
Target to Destabilize Thrombi
Peter Höök1, Rustem I. Litvinov2,3, Oleg V. Kim2,4, Shixin Xu4, Zhiliang Xu1, Joel S. Bennett5, 
Mark S. Alber4,6 & John W. Weisel2
The formation of platelet thrombi is determined by the integrin αIIbβ3-mediated interactions 
of platelets with fibrinogen and fibrin. Blood clotting in vivo is catalyzed by thrombin, which 
simultaneously induces fibrinogen binding to αIIbβ3 and converts fibrinogen to fibrin. Thus, after a 
short time, thrombus formation is governed by αIIbβ3 binding to fibrin fibers. Surprisingly, there is little 
understanding of αIIbβ3 interaction with fibrin polymers. Here we used an optical trap-based system 
to measure the binding of single αIIbβ3 molecules to polymeric fibrin and compare it to αIIbβ3 binding 
to monomeric fibrin and fibrinogen. Like αIIbβ3 binding to fibrinogen and monomeric fibrin, we found 
that αIIbβ3 binding to polymeric fibrin can be segregated into two binding regimes, one with weaker 
rupture forces of 30–60 pN and a second with stronger rupture forces >60 pN that peaked at 70–80 pN. 
However, we found that the mechanical stability of the bimolecular αIIbβ3-ligand complexes had the 
following order: fibrin polymer > fibrin monomer > fibrinogen. These quantitative differences reflect 
the distinct specificity and underlying molecular mechanisms of αIIbβ3-mediated reactions, implying 
that targeting platelet interactions with fibrin could increase the therapeutic indices of antithrombotic 
agents by focusing on the destabilization of thrombi rather than the prevention of platelet aggregation.
The formation of hemostatic plugs and obstructive thrombi are determined to a large extent by the integrin 
αIIbβ3-mediated interactions of platelets with fibrinogen and fibrin. The most studied of these interactions, fibrinogen 
binding to αIIbβ3, initiates platelet aggregation1. However, blood clotting in vivo is catalyzed by thrombin, which simul-
taneously induces fibrinogen binding to αIIbβ3 and converts fibrinogen to fibrin. Thus, after a short time period, the 
ligand for activated platelet αIIbβ3 binding is polymerized fibrin (p-fibrin) rather than fibrinogen or monomeric fibrin 
(m-fibrin)2–5. This is illustrated by the scanning electron micrograph of a blood clot formed by re-calcifying platelet-rich 
plasma shown in Fig. 1, in which fibrin strands emanate from platelet aggregates. This platelet-fibrin meshwork enables 
platelet-mediated clot retraction and has important functional consequences such as compression of clot-enmeshed 
erythrocytes causing a dramatic decrease of clot permeability6 and clot shrinkage enabling blood flow past otherwise 
obstructive thrombi7. Surprisingly, there is little understanding of αIIbβ3 interaction with fibrin polymers8,9. Previously, 
we used an optical trap-based system to measure the binding of single αIIbβ3 molecules to fibrinogen and m-fibrin10–13. 
Here, we extended these studies to αIIbβ3 binding to p-fibrin, finding that αIIbβ3 has a higher probability of forming 
mechanically stable interactions with p-fibrin than with fibrinogen. Targeting platelet binding to p-fibrin, rather than 
platelet aggregation, may be a way to increase the therapeutic indices of anti-platelet agents.
Results and Discussion
Model system to study interactions of polymerized fibrin with αIIbβ3. Quantitative measure-
ments of platelet binding to insoluble p-fibrin are difficult methodologically and conventional experimental 
approaches have been ineffective. Previously, we used optical trap-based force spectroscopy to determine the 
nanomechanics and two-dimensional kinetics of the interaction of αIIbβ3 with fibrinogen, m-fibrin, and the 
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fibrinogen-related peptides cRGDFK, and γC-1211–17. However, to measure the interaction of αIIbβ3 with pol-
ymeric rather than monomeric proteins, it was necessary to re-configure our optical trap system. In the re-con-
figured system, a fibrin clot was formed as a narrow strip in the center of a flow chamber (Fig. 2A), providing 
a hydrated interface for αIIbβ3 binding. Imaging the clots by confocal microscopy revealed a uniform network 
of high fiber density with well-defined edges allowing for precise visual control of contact with αIIbβ3-coated 
beads. The compressed appearance of the upper surface of the clot (Fig. 2B) resulted from preparation of the flow 
chamber in which a coverslip is gently pressed on top of the fibrin strip to prevent clot dehydration and to create 
a cover for the chamber. Because the top and bottom of the clot are extended laterally by slight compression, all 
optical trap experiments were conducted with a laser-trapped αIIbβ3-coated bead making repeated contacts 
with the planar surface of the clot at the center of the chamber where there is no compression (Fig. 2C). Rupture 
force signals generated during repeated contacts were then collected into 10 pN-wide bins and plotted against the 
average force for that bin after normalizing for the total number of interaction cycles.
Interactions between αIIbβ3 and polymerized fibrin. To validate our re-configured optical 
trap-based system, we measured rupture forces between movable latex beads coated with αIIbβ3 and silica ped-
estals coated irreversibly with either fibrinogen or m-fibrin. As we found previously, αIIbβ3-fibrinogen (Fig. 3G) 
Figure 1. Colorized scanning electron micrograph of blood clot made by re-calcifying platelet-rich plasma. 
Platelets and microvesicles are colored blue and fibrin is tan. The micrograph illustrates the specific and intimate 
interactions between platelets and fibrin in blood clots and demonstrates that most fibrin fibers originate from 
platelet aggregates, where much of the thrombin is generated, while platelet-derived microvesicles decorate the 
fibrin fibers.
Figure 2. (A) Schematic representation of the fibrin clot formed as a strip inside a flow chamber, providing 
a natural hydrated interface for binding of the integrin αIIbβ3. The clot is surrounded by a suspension of 
microscopic αIIbβ3-coated latex beads, one of which is trapped by the focused laser beam and oscillated to 
touch repeatedly the edge of the fibrin clot (see Methods). When the bead interacts with fibrin, the tension 
is produced and displayed as a force signal that is proportional to the strength of αIIbβ3-fibrin binding. (B) 
Z-stacked confocal microscopy images of the flow chamber and a lateral section of a fibrin clot spanning 100 µm 
of sample thickness. The clot was made from re-calcified plasma supplemented with Alexa-Fluor 488-labeled 
human fibrinogen. The compressed appearance of the clot results from the preparation of the flow chamber, 
such that a coverslip is placed and pressed down gently on top of the plasma strip to prevent clot dehydration 
and to create a cover for the chamber. Because the top and bottom of the clot are extended laterally by slight 
compression, all optical trap experiments were conducted with a trapped bead making contacts with the planar 
surface of the clot in the center of the chamber, where there is no compression as shown in B. (C) Top view. A 
latex bead (arrow) is shown making interactions with the surface edge of the fibrin clot.
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and αIIbβ3-m-fibrin (Fig. 3D) interactions had a characteristic bimodal rupture force distribution with rupture 
forces of up to 140 pN13. The rupture force distributions consisted of the sum of exponentially decreasing weak 
to moderate (20–60 pN) forces, and a Gaussian-like distribution of strong (>60 pN) rupture forces peaking at 
70–80 pN and were specific for αIIbβ3 binding because they were competitively inhibited by the free fibrinogen 
γC-dodecapeptide (γC-12) and by cRGDFK (Table 1, Fig. 3E,F,H,I). Because the pedestals were saturated with 
fibrinogen and m-fibrin, the probability of specific αIIbβ3 binding was determined primarily by the intrinsic 
reactivity of these ligands towards αIIbβ3. However, as we found previously, αIIbβ3 binding to m-fibrin-coated 
beads was only moderately sensitive to competitive inhibition by the γC-12 and cRGDFK, implying that αIIbβ3 
binding to m-fibrin could be mediated by binding sites other than the C-termini of the γ chains or either of the 
two α chain RGD motifs. Taken together, these rupture force measurements confirm that despite reversing the 
location of receptor and ligand, the re-configured system faithfully reproduces our previous results.
Figure 3. The panel of rupture force histograms in 10-pN wide bins of the interactions between Mn2+-activated 
αIIbβ3 integrin and polymerized fibrin (A–C), αIIbβ3 and monomeric fibrin (D–F), αIIbβ3 and fibrinogen 
(G–I) in the absence (A,D,G) and presence of an αIIbβ3 antagonist. Two competitive antagonists were used 
to suppress specific αIIbβ3-fibrin interactions: dodecapeptide (γC-12) that mimics the C-terminal AGDV-
containing 400–411 sequence of the fibrinogen γ chain (B,E,H) or the cyclic RGDFK peptide containing the 
Arg-Gly-Asp (RGD) integrin-binding motif that is present as residues 95–97 and 572–574 of the fibrin(ogen) 
(A)α chains (C,F,I). The rupture force profiles are segregated into three regimes, namely low forces <30 pN 
(shown as blank bins) that represent optical artifacts and/or non-specific background surface-to-surface 
interactions; moderate forces 30–60 pN (grey bins) representing the lower affinity αIIbβ3-fibrin(ogen) 
complexes, partially overlapped with the non-specific interactions; and high forces >60 pN (dark bins) 
representing higher affinity αIIbβ3-fibrin(ogen) complexes. The moderate forces are incompletely abrogated by 
the antagonists, while the strong forces are almost fully suppressed, corresponding to partial and full specificity, 
respectively. The total number of contacts is n = 9,685 for A, n = 5,871 for B, n = 8,967 for C, n = 11,344 for D, 
n = 8,937 for E, n = 9,633 for F, n = 10,386 for G, n = 7,926 for H, n = 6,937 for I.
www.nature.com/scientificreports/
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Next, we asked whether the interaction between beads covalently-coated with Mn2+-activated αIIbβ3 and an 
immobilized fibrin network produces measurable rupture forces and whether the rupture forces are similar to 
those generated when αIIbβ3 binds to immobilized m-fibrin13,15,16. As shown in Fig. 3A, the rupture force distri-
bution of αIIbβ3 bound to p-fibrin displayed two distinct regimes, one with weaker rupture forces of 30–60 pN 
and a second with stronger rupture forces >60 pN that peaked at 70–80 pN. These rupture force regimes are very 
similar to the force profiles resulting from αIIbβ3 bound to m-fibrin13, the major difference being a significantly 
higher cumulative binding probability for αIIbβ3 binding to m-fibrin throughout the entire force range likely 
due to either the increased density of immobilized m-fibrin and/or an enhanced on-rate for αIIbβ3 binding to 
m-fibrin versus p-fibrin (Table 1).
To insure that the rupture forces we measured resulted from specific αIIbβ3-p-fibrin interactions, we performed 
two sets of control experiments. First, we either inactivated αIIbβ3 using EDTA1,18 or replaced it with the irrelevant 
protein bovine serum albumin (BSA). While inactivating αIIbβ3 using EDTA or replacing it with BSA partially 
decreased rupture forces in the weaker force regime, rupture forces >60 pN were abrogated under both sets of con-
ditions (Table 1). Second, we inhibited αIIbβ3 binding to p-fibrin using eptifibatide, cRGDFK, and γC-1213,15. Each 
peptide decreased the cumulative binding probability in the weaker rupture force regime by ~50%, whereas their 
inhibitory effect on the stronger rupture forces was significantly greater (Table 1, Fig. 3B and C). Thus, the results 
suggest that a least a portion of the weaker rupture forces resulted from non-specific protein-protein interactions, 
whereas the stronger rupture forces results almost exclusively from the specific binding αIIbβ3 to p-fibrin. In sup-
port of this conclusion, we found that the probability of rupture forces >60 pN was significantly greater (p < 0.05) 
when experiments were performed using Mn2+-activated αIIbβ3 rather than the non-activated integrin (Table 1). It 
is noteworthy that purified αIIbβ3 consists of a mixture of low- and high-affinity forms, both of which are sensitive 
to the inhibitory effects of the antagonists, albeit with a different degree of susceptibility. Resting platelets adhere 
weakly to fibrinogen-coated surfaces, implying that αIIbβ3 is residing on the unstimulated cells in a low-affinity 
form that is still capable of interacting with fibrinogen and fibrin.
Kinetic model and parameters of the interaction of αIIbβ3 with polymerized fibrin. The 
bimodal distribution of rupture forces implies that αIIbβ3 interacts with the p-fibrin through a two-step mech-
anism similar to the way it interacts with fibrinogen19,20. In the latter case, αIIbβ3 exists in two interconvertible 
states, a lower affinity state R1 and a higher affinity state R2, corresponding to lower (LR1) and higher affinity (LR2) 
αIIbβ3-fibrinogen complexes. Further, it suggests that our two-state kinetic model for αIIbβ3 binding to fibrino-
gen19 can be applied to describe the dynamics of αIIbβ3 binding to p-fibrin as follows:
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where k1 is the forced unbinding rate of the lower affinity complexes and is approximated by the Bell model: 
= ( )k k exp fxK T1 10 B1  with k10 being the force-free unbinding rate and x1 being the critical elongation (or transition 
state distance) of the bond LR1. k2 is the forced unbinding rate of the higher affinity complexes and is approxi-
mated by = ( )k k exp m,fxK T2 20 B2  with k20 being the force-free unbinding rate and x2 being the critical transition 
state distance of the LR2 bond. r12 and r21 are the transition rates from LR1 to LR2 and vice versa. By letting P1 and 
Interacting molecules and conditions
Cumulative binding probability (%)
30–60 pN >60 pN
p-Fn/Mn2+-activated αIIbβ3 4.6 ± 0.9 3.2 ± 0.7
p-Fn/Mn2+-activated αIIbβ3 + γC-12 2.1 ± 0.5* 0.8 ± 0.2**
p-Fn/Mn2+-activated αIIbβ3 + cRGDFK 2.2 ± 0.7* 0.6 ± 0.2**
p-Fn/Mn2+-activated αIIbβ3 + EDTA 2.2 ± 0.8* 0.10 ± 0.06***
p-Fn/Mn2+-activated αIIbβ3 + eptifibatide 2.4 ± 0.7* 0.5 ± 0.2**
p-Fn/Non-activated αIIbβ3 4.7 ± 1.1 1.7 ± 0.5*
p-Fn/BSA 1.4 ± 0.4** 0.2 ± 0.1***
m-Fn/Mn2+-activated αIIbβ3 21 ± 2 22 ± 2
m-Fn/Mn2+-activated αIIbβ3 + γC-12 7.4 ± 2.1*** 12.3 ± 3.2***
m-Fn/Mn2+-activated αIIbβ3 + cRGDFK 5.1 ± 1.5*** 2.7 ± 1.2***
Fg/Mn2+-activated αIIbβ3 4.8 ± 0.8 3.6 ± 0.6
Fg/Mn2+-activated αIIbβ3 + γC-12 1.8 ± 0.6** 0.2 ± 0.1***
Fg/Mn2+-activated αIIbβ3 + cRGDFK 2.5 ± 0.3* 0.3 ± 0.1***
Table 1. Cumulative probability (M ± SD) of interactions between αIIbβ3 and polymerized fibrin (p-Fn), 
monomeric fibrin (m-Fn) and fibrinogen (Fg). *p < 0.05, **p < 0.01, ***p < 0.001 compared to Mn2+-activated 
integrin, unpaired two-tail t-test.
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P2 be the survival probabilities of states LR1 and L, the dynamics of the probabilities can be calculated by the fol-
lowing system19,
= − + +
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above equations can be simplified as in20
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The results of fitting the normalized experimental binding frequency distributions under rupture forces in the 
range 20–100 pN using Eq. (4) are shown in Fig. 4, confirming that the two-state model yields a good approxima-
tion of the experimental data.
The calculated unbinding rates and transition state distances are summarized in Fig. 4A. The experimental 
and modeled results point to notable differences in the affinity by which αIIbβ3 binds to fibrinogen vs p-fibrin. 
First, the force free unbinding rate of the low-affinity αIIbβ3-fibrinogen complex is 2–4 times greater than that 
of αIIbβ3 and p-fibrin. This could explain the relatively high frequency of αIIbβ3-fibrinogen dissociation at low 
rupture forces and the exponential decrease in unbinding under weak to moderate (20–60 pN) forces (Fig. 3G). 
Second, from the definition of the equilibrium constant, it follows that the initial probabilities of high-affinity state 
of αIIbβ3-fibrin interactions (0.0140 for p-fibrin, and 0.0181 for m-fibrin) are 2-3x larger than αIIbβ3-fibrinogen 
(0.0063). This could explain why αIIbβ3-fibrin is more stable under high rupture force (>60 pN). Further, the 
lower force-free unbinding rates in αIIbβ3-p-fibrin interactions compared with those between αIIbβ3 and 
m-fibrin suggests that a more stable interaction with the αIIbβ3 is attained after fibrin polymerizes.
To summarize, we found that like αIIbβ3 binding to fibrinogen and m-fibrin, αIIbβ3 binding to p-fibrin 
can be segregated into two binding regimes that reflect lower- and higher-affinity activation states of αIIbβ3. 
Although the higher maximal rupture forces of αIIbβ3 bound to fibrinogen and m-fibrin suggest that αIIbβ3 
binding to these ligands is stronger than binding to p-fibrin, the smaller forces in the p-fibrin histograms are likely 
due to the formation of multiple αIIbβ3-fibrin bonds with higher binding forces (140 pN) beyond the maximal 
power of the optical trap. Similarly, the lower binding probability reflects the formation of multiple αIIbβ3 bonds 
that were unmeasurable and missing in the registered rupture force spectra. This presumption is supported by 
the computed mechanical stability of the bimolecular αIIbβ3-ligand complexes, which has the following order: 
fibrin polymer > fibrin monomer > fibrinogen. These quantitative differences reflect the distinct specificity and 
underlying molecular mechanisms of αIIbβ3-mediated reactions, implying that targeting platelet interactions 
with fibrin could increase the therapeutic indices of antithrombotic agents by focusing on destabilization of devel-
oping or formed thrombi rather than prevention of platelet aggregation. We recently demonstrated differences 
in the binding specificity between αIIbβ3-Fg and αIIbβ3-m-Fn interactions13. We found that the number of 
integrin-binding sites in m-fibrin is not limited to its RGD and γC-12 motifs and that at least three potential 
integrin-binding motifs that become exposed upon Fg to Fn conversion and are potential targets to specifically 
inhibit the interaction of activated platelets with p-Fn.
Materials and Methods
Optical trap-based force spectroscopy. Our model system designed to measure the nanomechanics of 
bimolecular interactions is based on a custom-built optical trap previously described in detail15 with some mod-
ifications. This system permits studies of single-molecule force-induced unbinding between two surfaces coated 
with interacting proteins; one surface is motionless and the other consists of a laser-trapped oscillating micro-
sphere (bead). The core of the laser trap system is a Zeiss Axio Observer A1 inverted microscope and a 60 × 1.3 
numerical aperture Fluor lens combined with an FCBar Nd:YAG laser (λ = 1,064 nm) with 4Ws of power in con-
tinuous TEM-00 mode. A computer-operated two-dimensional acousto-optical deflector is used to control the 
trap position and hence the position of the trapped bead. The force exerted by the trap on the bead displaced from 
the laser beam focus is measured with a quadrant detector. The system enables control of the bead/trap oscillation 
frequency and amplitude, the magnitude of the compressive force, and the magnitude of the tensile force during 
dissociation of the surfaces coated with interacting molecules. All experiments are conducted at an average trap 
stiffness of 0.10 ± 0.02 pN/nm as computed from measurements of the bandwidth of Brownian motion for dif-
ferent beads21. Custom-written software on the LabVIEW® platform (National Instruments, Austin, TX) is used 
to control and record laser beam deflection, move the piezoelectric stage (Queensgate, Birkshire, UK), and for 
subsequent off-line data analysis.
www.nature.com/scientificreports/
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Measurement of the interaction of αIIbβ3 with fibrinogen or fibrin at the single-molecule 
level. We measured the interaction of single αIIbβ3 molecules with fibrinogen or fibrin monomer using a 
modification of our optical trap-based force spectroscopy system11–17 in which purified αIIbβ3 was immobilized 
on freely-moving latex beads, while fibrinogen or monomeric fibrin was bound to silica beads attached to the 
bottom of a fluid-filled flow chamber. Under visual microscopic control, a bead coated with αIIbβ3 was trapped 
by a focused laser beam and moved in an oscillatory manner so that it tapped a stationary fibrinogen- or fibrin 
monomer-coated pedestal (Fig. 1). When the immobilized αIIbβ3 on the bead interacted with fibrinogen or 
fibrin monomer on the pedestal, tension was produced when the bead was displaced from the laser focus until 
the αIIbβ3-ligand bond ruptured. The applied force was then displayed as a signal proportional to the strength 
of αIIbβ3-ligand binding. Such signals were on the order of picoNewtons and quantitatively characterize the 
interactions of αIIbβ3 with fibrinogen or fibrin monomer at the nanomechanical molecular level. The key modi-
fication that enabled us to measure the interaction of αIIbβ3 with polymeric fibrin was that the motionless surface 
was not a fibrinogen or fibrin-coated pedestal, but a fibrin clot formed inside a flow chamber. Then one freely 
moving αIIbβ3-coated bead was trapped by a focused laser beam, brought close to the fibrin clot, and oscillated 
with a triangular waveform in order to repeatedly touch the edge of the clot, mimicking the physical interaction 
of an activated platelet with a fibrin network.
Coating latex beads with αIIbβ3. Purified human αIIbβ3 (Abcam, Cambridge, MA) at 1 mg/ml in 
20 mM HEPES, pH 7.4, containing 150 mM NaCl, 1 mM CaCl2 and 30 mM 30 mM n-octyl-β-D-glucoside, was 
activated with 1 mM MnCl2 for 30 min at 37 °C. The activated αIIbβ3 was covalently attached to 2.0 µm in diam-
eter carboxylate-modified latex beads (Bangs Laboratories, Fishers, IN) using N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride as a crosslinking agent in a two-step procedure. The beads were activated 
by mixing 1 ml of the 0.1 M 2-(N-morpholino)ethanesulphonic acid, pH 5.2, 20 µl of a 10% bead suspension and 
3 mg of dry carbodiimide, followed by constant shaking for 15 min at room temperature. The activated beads were 
sedimented at 4,000 g for 2 min, washed once with binding buffer (0.055 M borate buffer, pH 8.5), sedimented 
again, and re-suspended in 1 ml of 50 µg/ml Mn2+-activated αIIbβ3 in the binding buffer. After a 30 min incu-
bation with stirring at room temperature, the beads were sedimented and resuspended in 1 ml of bovine serum 
albumin (2 mg/ml in 0.055 M borate buffer, pH 8.5) to block the remaining active groups. Following this protocol, 
the surface density of functional αIIbβ3 molecules capable of binding 125I-fibrinogen was found to be 3,072 ± 412 
molecules/µm2. αIIbβ3-coated beads were freshly prepared and mildly sonicated to disrupt aggregates before 
each experiment.
Figure 4. (A) Analytic approximation parameters for the interactions between Mn2+-activated αIIbβ3 integrin 
(In) and polymeric fibrin (p-Fn), monomeric fibrin (m-Fn) and fibrinogen (Fg), respectively. (B) Experimental 
rupture force profiles (symbols) of the interactions of αIIbβ3 with polymeric fibrin (p-Fn), monomeric fibrin 
(m-Fn), and fibrinogen (Fg) fitted to the Bell function (see Supplementary Information). Signals that appeared 
as forces below 20 pN, corresponding to optical artifacts and non-specific binding events were excluded from 
the analysis. The total number of contacts is n = 5,871 for p-Fn, n = 11,344 for m-Fn, and n = 10,386 for Fg. The 
numerical parameters extracted from the fitting analysis are presented in (A).
www.nature.com/scientificreports/
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Coating silica pedestals with fibrinogen and monomeric fibrin. Purified human fibrinogen (Hyphen 
BioMed, France) was bound covalently to 5-µm spherical silica pedestals anchored to the bottom of a chamber as 
previously described11,13,15. Briefly, pedestals coated with a thin layer of polyacrylamide were activated with 10% 
glutaraldehyde (30 min, 37 °C), after which fibrinogen (1 mg/ml in the activation mixture) was immobilized for 2 
hr at 4 °C. The chamber was then washed with 20 volumes of the same buffer to remove non-covalently adsorbed 
protein, blocked with 2 mg/ml bovine serum albumin (BSA) in 0.055 M borate buffer, pH 8.5, 150 mM NaCl, 
3 mM CaCl2 for 30 min at 4 °C, and equilibrated with 20 mM HEPES buffer, pH 7.4, containing 150 mM NaCl. 
To generate surfaces coated with monomeric fibrin, the fibrinogen-coated pedestals were treated with human 
α-thrombin (1 U/ml, 37 °C, 1 hr) followed by thorough washing (20 volumes of the flow chamber) and equilibra-
tion in 0.1 M HEPES buffer, pH 7.4, containing 150 mM NaCl, 3 mM CaCl2, 1 mM MnCl2, 2 mg/ml BSA, and 0.1% 
(v/v) Triton X-100. Treatment with thrombin has been previously shown to generate biologically active fibrin 
molecules on the bead surface10,22. Because the monomeric fibrin was covalently attached to the bead surface, 
substantial fibrin oligomerization was not possible.
Formation of a fibrin clot inside a flow chamber. A fibrin network was formed using either purified 
human fibrinogen or platelet-poor plasma obtained from citrated human whole blood by centrifugation at 1,500 g 
for 15 minutes at room temperature. Plasma samples from more than 10 healthy donors were pooled, aliquoted, 
and frozen. A new aliquot was thawed at 37 °C for 30 min before use. The plasma was re-calcified with 25 mM 
CaCl2 and 10 µl was immediately applied as a strip in the center of a microscopic flow chamber (Fig. 1). After 
30 min at 37 °C in a humid atmosphere, a clot with well-defined boundaries was formed. To prevent drying of the 
clot, assay buffer [0.1 M HEPES, pH 7.4, 2 mg/ml BSA, and 0.1% (v/v) Triton X-100] was flowed into the cham-
ber after clot formation. The clot was then kept at 4 °C for 1–4 hours before use. To compare experimental data 
obtained with fibrin from plasma with fibrin made from purified fibrinogen, 1 mM CaCl2 and 0.5 U/ml thrombin 
(ERL, South Bend, IN) were added to 1 mg/ml purified fibrinogen in 20 mM HEPES buffer, pH 7.4, containing 
150 mM NaCl. 10 µl of the mixture was immediately applied to an experimental flow chamber and allowed to clot. 
Following clot formation, the chamber was filled with the assay buffer, and used on the same day of the experi-
ment in the same conditions as plasma clots.
Fluorescent confocal microscopy of fibrin clots. For morphological characterization of the fibrin 
clot, Alexa-Fluor 488-labeled human fibrinogen (Molecular Probes, Grand Island, NY) was added to plasma at 
a final concentration of 0.04 mg/ml before re-calcification and clot formation. The fibrin clot was imaged using 
Zeiss LSM710 laser scanning confocal microscope equipped with a Plan Apo 40x water immersion objective lens 
(N/A = 1.2) to provide high-resolution z-stack images spanning 100 µm of sample thickness. An argon laser beam 
with wavelength of 488 nm was used for fluorescent and reflectance confocal microscopy of the labeled fibrin. The 
z-stack distance between slices was set as 0.5 µm with 1024 × 1024 pixels resolution for each slice.
Measurement of αIIbβ3-fibrin binding strength. All measurements were conducted in an assay 
buffer composed of 0.1 M HEPES, pH 7.4, 2 mg/ml BSA, and 0.1% (v/v) Triton X-100. 1 µl of the αIIbβ3-coated 
latex bead suspension (107 beads/ml) in 50 µl of assay buffer was flowed into the chamber containing a either 
fibrin-coated pedestals or pre-formed fibrin clot. The chamber was then placed on the microscope stage of the 
optical trap setup, a single αIIbβ3-coated latex bead was trapped by the focused laser beam and moved manually 
to within 1–2 µm of the edge of a pedestal or a fibrin network. After beginning oscillation of the bead, the distance 
between the bead and the interacting surface was reduced in 20-nm steps using a piezostage until they touched 
each other repeatedly, allowing for direct interactions between the surface-attached αIIbβ3 and either monomeric 
fibrin or polymerized fibrin fibers. The position of the optical trap was oscillated in a triangular waveform at 5 Hz 
and constant peak-to-peak amplitude of 800 nm. The tension produced when an αIIbβ3 molecule on the latex 
bead interacted with fibrin was sensed and displayed as a force signal that was proportional to the strength of 
αIIbβ3-fibrin binding.
Data processing and analysis. Rupture force signals from several tens of αIIbβ3-coated beads interact-
ing with fibrin were collected for each experimental condition, so the total number of touching events analyzed 
varied from 103 to about 105. Individual forces measured during each contact-detachment cycle were collected 
into 10-pN-wide bins and plotted against the average force for that bin after normalizing for the total number of 
interaction cycles. The percentage of events in a particular force range (bin) represents the frequency (probability 
density) of rupture events at that tension. Optical artifacts observed with or without trapped latex beads produce 
signals that appeared as forces below 10 pN. Accordingly, rupture forces in this range were not considered when 
the data were analyzed.
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